CTLA-4 mAb (9D9), InVivoPure

ID: AK3609P Category:

The CTLA-4 antibody (clone 9D9) is a monoclonal antibody that specifically targets the mouse CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), also known as CD152.

This antibody is produced exclusively under serum-free conditions from hybridoma and purified with Protein-A or Protein-G affinity chromatography.

In stock

Delivery time: 2-5 days

From: 130,00 € Excl. VAT and delivery costs

Please contact us for larger quantities.

Endotoxin level ≤ 2 EU/mg

The CTLA-4 antibody (clone 9D9) is a monoclonal antibody that specifically targets the mouse
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), also known as CD152. CTLA-4 is a 33 kDa cell
surface receptor, belonging to the CD28 family of the immunoglobulin superfamily.
CTLA-4 plays a crucial role in immune regulation. 9D9 blocks the binding of murine CTLA-4-Ig to
B7-1-positive cells. It has an inhibitory effect and acts as an “off switch” for T cells. It binds to
the ligands CD80 and CD86 on antigen-presenting cells (APCs) and thereby inhibits the
activation of T cells. The CTLA-4 antibody clone 9D9 has been used to block CTLA-4 and
has been shown to enhance T-cell immunity against tumors.

This antibody is produced exclusively under serum-free conditions from hybridoma and
purified with Protein-A or Protein-G affinity chromatography.

 

Product-ID: AK3609P
Clone: 9D9
Immunogen: Not known
Host: Mouse
Clonality: Monoclonal
Isotype: Mouse IgG2b
Formulation: Clear Liquid, PBS, pH 7.4, 0.2 μm sterile filtered
Concentration: ≥ 1.00 mg/mL
Purity: ≥ 90 % (CGE, reducing conditions)
≤ 10 % aggregates (analytical SEC)
Endotoxin: ≤ 2 EU/mg (LAL test)
Storage: 2 - 8 °C
Recommended Isotype Control: Mouse IgG2b ĸ Isotype Control (AK3456P)

 

The product is for research use only and not for use in diagnostic or therapeutic procedures.

Additional information

Literature

[1] Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok
JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells
co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26;210(9):1695-710.
doi: 10.1084/jem.20130579. Epub 2013 Jul 29. PMID: 23897981; PMCID: PMC3754863.
[2] Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of
IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer
Immunol Res. 2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013. Epub 2013 Apr 7. PMID: 24777248.
[3] Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters
the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006 Jul;116(7):1935-45. doi:
10.1172/JCI27745. Epub 2006 Jun 15. PMID: 16778987; PMCID: PMC1479425.
Document

Product Information Sheet – AK3609P
Notice

The product is for research use only and not for use in diagnostic or therapeutic procedures.

Reviews

There are no reviews yet.

Be the first to review “CTLA-4 mAb (9D9), InVivoPure”